94 related articles for article (PubMed ID: 1528048)
21. Direct demonstration of three different states of the pancreatic cholecystokinin receptor.
Talkad VD; Fortune KP; Pollo DA; Shah GN; Wank SA; Gardner JD
Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1868-72. PubMed ID: 8127897
[TBL] [Abstract][Full Text] [Related]
22. Chronic administration of a potent cholecystokinin receptor antagonist, L-364,718, fails to inhibit pancreas growth in preweanling rats.
Wisner JR; Ozawa S; Xue BG; Renner IG
Pancreas; 1990 Jul; 5(4):434-8. PubMed ID: 1696382
[TBL] [Abstract][Full Text] [Related]
23. High-affinity CCK-A receptors on the vagus nerve mediate CCK-stimulated pancreatic secretion in rats.
Li Y; Hao Y; Owyang C
Am J Physiol; 1997 Sep; 273(3 Pt 1):G679-85. PubMed ID: 9316472
[TBL] [Abstract][Full Text] [Related]
24. Characterization of a new diphenylpyrazolidinone cholecystokinin antagonist in vitro isolated rat pancreatic acini.
Akiyama T; Tachibana I; Otsuki M
Int J Pancreatol; 1993 Oct; 14(2):167-73. PubMed ID: 7506744
[TBL] [Abstract][Full Text] [Related]
25. Characterization of the three different states of the cholecystokinin (CCK) receptor in pancreatic acini.
Talkad VD; Patto RJ; Metz DC; Turner RJ; Fortune KP; Bhat ST; Gardner JD
Biochim Biophys Acta; 1994 Oct; 1224(1):103-16. PubMed ID: 7524683
[TBL] [Abstract][Full Text] [Related]
26. Exocrine effects of the CCK antagonist L-364,718 in canine pancreatic autografts.
Garvin PJ; Niehoff ML; Burton FR; Dysarz FA; Meadow R; Solomon H
J Surg Res; 1996 Feb; 61(1):256-9. PubMed ID: 8769975
[TBL] [Abstract][Full Text] [Related]
27. Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260.
O'Neill MF; Dourish CT; Iversen SD
Eur J Pharmacol; 1991 Feb; 193(2):203-8. PubMed ID: 2050197
[TBL] [Abstract][Full Text] [Related]
28. Stimulation of both CCK-A and CCK-B receptors activates MAP kinases in AR42J and receptor-transfected CHO cells.
Dabrowski A; Detjen KM; Logsdon CD; Williams JA
Digestion; 1997; 58(4):361-7. PubMed ID: 9324163
[TBL] [Abstract][Full Text] [Related]
29. Effects of endogenous and exogenous cholecystokinin and of infusion with the cholecystokinin antagonist L-364,718 on pancreatic and gastrointestinal growth.
Axelson J; Håkanson R; Ihse I; Lilja I; Rehfeld JF; Sundler F
Scand J Gastroenterol; 1990 May; 25(5):471-80. PubMed ID: 2359975
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the effects of two cholecystokinin-receptor antagonists, loxiglumide and L-364,718, on the pancreatic secretory response to intraduodenal tryptophan in dogs.
Niebergall-Roth E; Teyssen S; Wetzel D; Hartel M; Beglinger C; Riepl RL; Singer MV
Scand J Gastroenterol; 1996 Jul; 31(7):723-32. PubMed ID: 8819225
[TBL] [Abstract][Full Text] [Related]
31. Nucleoside diphosphate kinase associated with rat pancreatic membranes regulates CCK receptor affinity.
Blevins GT; van de Westerlo EM; Williams JA
Am J Physiol; 1994 Nov; 267(5 Pt 1):G866-74. PubMed ID: 7977749
[TBL] [Abstract][Full Text] [Related]
32. Endogenous cholecystokinin release responsible for pancreatic growth observed after pancreatic juice diversion.
Rivard N; Guan D; Maouyo D; Grondin G; Bérubé FL; Morisset J
Endocrinology; 1991 Dec; 129(6):2867-74. PubMed ID: 1954873
[TBL] [Abstract][Full Text] [Related]
33. Effects of a high-fat diet and L364,718 on growth of human pancreas cancer.
Smith JP; Kramer S; Bagheri S
Dig Dis Sci; 1990 Jun; 35(6):726-32. PubMed ID: 2344806
[TBL] [Abstract][Full Text] [Related]
34. Influence of gastrin on human astrocytic tumor cell proliferation.
Camby I; Salmon I; Danguy A; Pasteels JL; Brotchi J; Martinez J; Kiss R
J Natl Cancer Inst; 1996 May; 88(9):594-600. PubMed ID: 8609660
[TBL] [Abstract][Full Text] [Related]
35. The effect of bombesin, cholecystokinin, gastrin, and their antagonists on proliferation of pancreatic cancer cell lines.
Ohlsson B; Fredäng N; Axelson J
Scand J Gastroenterol; 1999 Dec; 34(12):1224-9. PubMed ID: 10636070
[TBL] [Abstract][Full Text] [Related]
36. Biochemical regulation of the three different states of the cholecystokinin (CCK) receptor in pancreatic acini.
Pandya PK; Huang SC; Talkad VD; Wank SA; Gardner JD
Biochim Biophys Acta; 1994 Oct; 1224(1):117-26. PubMed ID: 7948036
[TBL] [Abstract][Full Text] [Related]
37. Biological effects of newly synthesized cholecystokinin analogs.
Verspohl EJ; LaMura M
Horm Res; 2000; 53(4):177-84. PubMed ID: 11044801
[TBL] [Abstract][Full Text] [Related]
38. Effects of peptide YY on CCK/CCK antagonist interactions in cerulein-induced pancreatic injury.
Tito JM; Rudnicki M; Robinson DC; Guiney WB; Adrian TE; Gold MS
Ann N Y Acad Sci; 1995 May; 757():410-2. PubMed ID: 7541974
[No Abstract] [Full Text] [Related]
39. Characterization of type A and type B CCK receptor binding sites in rat vagus nerve.
Corp ES; McQuade J; Moran TH; Smith GP
Brain Res; 1993 Sep; 623(1):161-6. PubMed ID: 8221086
[TBL] [Abstract][Full Text] [Related]
40. Influence of CCK antagonist L-364,718, pancreastatin (33-49) and a somatostatin analogue on camostate-induced rat pancreatic hypertrophy.
Schmidt WE; Stöckmann F; Choudhury AR; Wilms HM; Siegel EG; Nustede R; Fölsch UR; Creutzfeldt W
Digestion; 1989; 44(2):105-16. PubMed ID: 2612749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]